Odds ratios are frequently used for estimating the effect of an exposure on the probability of disease in case-control studies. In planning such studies, methods for sample size determination are required to ensure sufficient accuracy in estimating odds ratios once the data are collected. Often, the exposure used in epidemiologic studies is not perfectly ascertained. This can arise from recall bias, the use of a proxy exposure measurement, uncertain work exposure history, and laboratory or other errors. The resulting misclassification can have large impacts on the accuracy and precision of estimators, and specialized estimation techniques have been developed to adjust for these biases. However, much less work has been done to account for the anticipated decrease in the precision of estimators at the design stage. Here, we develop methods for sample size determination for odds ratios in the presence of exposure misclassification by using several interval-based Bayesian criteria. By using a series of prototypical examples, we compare sample size requirements after adjustment for misclassification with those required when this problem is ignored. We illustrate the methods by planning a case-control study of the effect of late introduction of peanut to the diet of children to the subsequent development of peanut allergy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/aje/kwt181 | DOI Listing |
Nanoscale Adv
January 2025
Department of Production Engineering, Faculty of Mechanical Engineering, University of Aleppo Aleppo Syria
Adverse reactions caused by waterborne contaminants constitute a major hazard to the environment. Controlling the pollutants released into aquatic systems through water degradation has been one of the major concerns of recent research. Bismuth-based perovskites have exhibited outstanding properties in the field of photocatalysis.
View Article and Find Full Text PDFCJC Open
February 2024
CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Background: Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.
Methods: Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42).
BMJ Oncol
October 2023
Department of Pathology, University of California San Francisco, San Francisco, California, USA.
Objective: In Barrett's oesophagus (BE), after radiofrequency ablation (RFA), the oesophagus can be repopulated with a stratified 'neosquamous epithelium' (NeoSE). While histologically normal, the origin and clonal make-up of this NeoSE is unknown. An increased understanding of NeoSE is important as some studies suggest that NeoSE is biologically abnormal.
View Article and Find Full Text PDFOphthalmol Sci
November 2024
Department of Ophthalmology, National Center for Global Health and Medicine, Tokyo, Japan.
Objective: To evaluate the effect of disease stage, frequency and clustering of visual field (VF) tests, inclusion of 1 or both eyes, and 1 (1 arm; before and after a treatment) or 2 groups (2 arms; treatment and control arm) on sample size calculation in clinical trials.
Design: Clinical cohort study.
Participants: A series of VFs were simulated based on test-retest VF data in the early, moderate, and advanced stages of glaucoma with 231, 204, and 226 eyes, respectively.
Objective: Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug.
Background: Creating a novel chemotherapy is costly both in time and capital spent for drug manufacturers. To regenerate what they've spent, drug manufacturers may attempt to repurpose their medications for new indications via clinical trials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!